41 – 50 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
(
- Contribution to journal › Article
-
Mark
A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen.
(
- Contribution to journal › Article
-
Mark
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
(
- Contribution to journal › Article
- 2010
-
Mark
Ki-67 as a long-term prognostic factor in lobular breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Evidence for tissue factor phosphorylation and its correlation with protease activated receptor expression and the prognosis of primary breast cancer.
(
- Contribution to journal › Article
- 2009
-
Mark
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
2009) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22. p.1564-1574(
- Contribution to journal › Article
-
Mark
Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer.
(
- Contribution to journal › Article
- 2008
-
Mark
Epidermal Growth Factor Receptor (EGFR) in primary breast cancer-protein expression, but not gene copy number, gives important prognostic information in tamoxifen treated patients
2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.187-187(
- Contribution to journal › Published meeting abstract
-
Mark
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
(
- Contribution to journal › Article